Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. IONQ
2. SPY
3. AAPL
4. ACN
5. IONS
6. AZN
7. ROIV
8. HOOD
9. QCOM
10. NVDA

Go back to Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
(NASDAQ: KURA) Delayed: 12.80 -0.45 (3.4%)
Previous Close $13.25    52 Week High $8.90 
Open $12.93    52 Week Low $2.50 
Day High $12.93    P/E N/A 
Day Low $12.50    EPS $0.00 
Volume 500,689